Free Subscription

  • Access daily briefings and unlimited news articles

Premium

Only $39.95 per year
  • Quarterly magazine and digital
  • Indepth executive interviews
  • Unlimited news and insights
  • Expert opinion and analysis

Johnson & Johnson

Johnson & Johnson Archives

Johnson & Johnson ordered to pay US$8 billion over Risperdal side effects

Plaintiff claims J&J's antipsychotic drug Risperdal can cause abnormal growth of female breast tissue in boys.

Johnson & Johnson cans CMO role as Alison Lewis departs

The consumer goods giant is streamlining priorities under a new business model.

This week in FMCG

The top headlines from this week.

J&J ordered to pay US$29m in talc trial

Latest defeat for the healthcare conglomerate which is facing over 13,000 similar lawsuits nationwide.

J&J forecasts sales to slow in 2019

The healthcare conglomerate beat expectations for the fourth quarter of 2018.

Latest J&J talc trial underway

Plaintiff alleges J&J talc product caused mesothelioma.

J&J CEO responds to asbestos report

Consumer goods company moves to reassure consumers that its products are safe.

J&J knew about asbestos in its baby powder for decades

The company withheld the information from regulators and the public.

J&J extends QUT collaboration

The three year extension will allow for continued life-science innovative research.

Johnson & Johnson addresses plastic waste problem

FMCG giant signs New Plastics Economy Global Commitment.

Johnson & Johnson sells LifeScan for $2.1bn

FMCG giant will still continue to create products for consumers with diabetes.

This week in FMCG

What happened across the Australian business sector this week?

This week in FMCG

What happened this week in Australia's fast moving consumer goods sector?

Johnson & Johnson receives $2 billion offer to acquire LifeScan, Inc.

LifeScan manufactures blood glucose monitoring products.

Johnson & Johnson tops forecasts

Healthcare company Johnson & Johnson profit surpasses Wall Street expectations.

Johnson & Johnson surpasses Q1 forecasts

Johnson & Johnson beats analyst's forecast for the first quarter.

NZ watchdog rejects lubricants merger

Commerce Commission rules out Reckitt Benckiser's proposal to purchase Johnson & Johnson’s K-Y brand.